Dyadic International DYAI
Dyadic International Q2 FY26: revenue $961K, down 1%; diluted EPS −$0.06
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001493152-26-037258
Key figures from this report
These are the numbers Dyadic International reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$961K−1% from $967K in Q2 FY2510-Q income statement, on EDGAR
- Net income−$2.1MAgainst −$1.8M in Q2 FY2510-Q income statement, on EDGAR
- Diluted EPS−$0.06Against −$0.06 in Q2 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$1.4M−33% from $2.1M in Q2 FY25Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$1.8MAgainst −$130K in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Aytu Biopharma AYTU public float $24M, Dec 31, 2025
- Kala Bio KALA public float $25M, Jun 30, 2025
- Lexaria Bioscience LEXX public float $25M, Feb 28, 2025, over 18 months old
- Tenax Therapeutics TENX public float $24M, Jun 30, 2025
- Nanoviricides NNVC public float $24M, Dec 31, 2025